Adenoviral-Mediated Suicide Gene Therapy for Ovarian Cancer

This publication has 18 references indexed in Scilit:

• Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors
  Molecular Therapy, 2000
• Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector—producer cells followed by intravenous ganciclovir administration
  Journal of Neurosurgery, 2000
• A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma
  Human Gene Therapy, 1998
• A Phase I/II Dose-Escalation Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Metastatic Melanoma
  Human Gene Therapy, 1998
• Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma
  Human Gene Therapy, 1998
• Gene therapy: ovarian carcinoma as the paradigm.
  American Journal of Clinical Pathology, 1998
• A Phase I Study of Recombinant Adenovirus Vector-Mediated Intraperitoneal Delivery of Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene and Intravenous Ganciclovir for Previously Treated Ovarian and Extraovarian Cancer Patients. University of Alabama Comprehensive Cancer Center, Birmingham, AL
  Human Gene Therapy, 1997
• Adenovirus-mediated gene therapy of ovarian cancer in a mouse model
  American Journal of Obstetrics and Gynecology, 1996
• Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma
  Journal of Molecular Medicine, 1996
• In VivoGene Therapy of Ovarian Cancer by Adenovirus-Mediated Thymidine Kinase Gene Transduction and Ganciclovir Administration
  Gynecologic Oncology, 1996